Save time and jump to the most important pieces.
Date | Price Target | Rating | Analyst |
---|---|---|---|
10/30/2024 | $200.00 | Neutral → Buy | Seaport Research Partners |
10/11/2024 | $212.00 | Sector Outperform | Scotiabank |
10/1/2024 | $215.00 | Buy | Pivotal Research Group |
7/10/2024 | $200.00 → $220.00 | Buy | TD Cowen |
6/28/2024 | $181.00 | Buy → Neutral | Rosenblatt |
4/8/2024 | $172.00 → $185.00 | Outperform | Oppenheimer |
12/20/2023 | $150.00 | Outperform | Raymond James |
1/31/2023 | $116.00 → $119.00 | Buy | BofA Securities |
4 - Alphabet Inc. (0001652044) (Issuer)
4 - Alphabet Inc. (0001652044) (Issuer)
4 - Alphabet Inc. (0001652044) (Issuer)
8-K - Alphabet Inc. (0001652044) (Filer)
DEFA14A - Alphabet Inc. (0001652044) (Filer)
8-K - Alphabet Inc. (0001652044) (Filer)
Seaport Research Partners upgraded Alphabet from Neutral to Buy and set a new price target of $200.00
Scotiabank initiated coverage of Alphabet with a rating of Sector Outperform and set a new price target of $212.00
Pivotal Research Group initiated coverage of Alphabet with a rating of Buy and set a new price target of $215.00
SC 13G/A - Alphabet Inc. (0001652044) (Subject)
SC 13G/A - Alphabet Inc. (0001652044) (Subject)
SC 13G/A - Alphabet Inc. (0001652044) (Subject)
Wellteq Digital Health Inc. (CSE:WTEQ, OTCQB:WTEQF) increases its investment into sleep solution capabilities, as one of its four behavioural levers of health coaching. Wellteq has signed a perpetual license agreement for sleep chronotype assessments and education content from one of Asia Pacific's leading sleep technology companies. Wellteq intends to promptly integrate newly licensed sleep assets into the existing corporate health solution and accelerate development of clinical sleep solutions. Initial transaction terms have been adjusted downward from AU$600,000 to CA$70,000 to reflect the unrestricted perpetual license versus an acquisition. This license accelerates Wellteq's s
USA News Group News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, April 29, 2025 /CNW/ -- Artificial intelligence is making deeper inroads into western healthcare, targeting the slow grind of authorizations and paperwork that bog down patient care. Despite Bill Gates' prophecy about AI replacing doctors, the real push today is about supercharging physicians, not sidelining them. Recent moves by players such as like Avant Technologies, Inc. (OTCQB:AVAI), Amesite Inc. (NASDAQ:AMST), Oracle Corporation (NYSE:ORCL), Clover Health Investments, Corp. (NASDAQ:CLOV), and Alphabet Inc. (NASDAQ:GOOG, GOOGL)) are signaling just how fast this transformation is taking hold.
USA News Group News Commentary Issued on behalf of Avant Technologies Inc. VANCOUVER, BC, April 29, 2025 /PRNewswire/ -- Artificial intelligence is making deeper inroads into western healthcare, targeting the slow grind of authorizations and paperwork that bog down patient care. Despite Bill Gates' prophecy about AI replacing doctors, the real push today is about supercharging physicians, not sidelining them. Recent moves by players such as like Avant Technologies, Inc. (OTCQB:AVAI), Amesite Inc. (NASDAQ:AMST), Oracle Corporation (NYSE:ORCL), Clover Health Investments, Corp. (NASDAQ:CLOV), and Alphabet Inc. (NASDAQ:GOOG, GOOGL)) are signaling just how fast this transformation is taking hold.
TROY, Mich., April 22, 2025 /PRNewswire/ -- Meta Platforms Inc.'s – Facebook's corporate name -- recent report has investors wondering if the company's stock is overvalued. Or is it in the buy range? As such, the Editorial Advisory and Securities Review Committee of BetterInvesting Magazine considers Meta Platforms (NASDAQ:META) as worthy of further study and has named the company its "Stock to Study" for the June/July 2025 double issue for investors' informational and educational use. The fundamental data is eye-opening; investors can view Meta's sales, earnings, pre-tax profit, return on equity, and more all on one page, courtesy of the National Association of Investors, at: https://ssg.
Board addition brings strong tech industry expertise to advance the company's Pathway to Thrive business strategy The Chemours Company (Chemours) (NYSE:CC), a global leader in delivering innovative performance chemistry, today announced the appointment of Joseph (Joe) Kava to its Board of Directors, effective January 3, 2025. Joe brings three decades of experience gained in leadership, operational, and technical roles at some of the world's leading technology companies. He currently serves as Vice President of Data Centers at Google (NASDAQ:GOOG), where he has overseen site selection, design, construction management, operations, power purchasing, engineering, facility and hardware appli
PALO ALTO, Calif., July 18, 2024 /PRNewswire/ -- HiHello, the world's first software platform for digital brand and identity, is thrilled to announce the addition of Shana Simmons and Eugenio Pace to its Board of Directors. Their appointments bring unparalleled expertise and strategic vision to HiHello as the company continues its mission to revolutionize professional networking with an enterprise-ready platform for modern digital business cards. Shana Simmons, who recently joined Zendesk as Chief Legal Officer, brings over 15 years of experience in legal leadership and corporate governance. Prior to Zendesk, Shana served as Chief Legal Officer at Everlaw, a cloud-based e-discovery software
MoneyLion ("MoneyLion") (NYSE:ML), a financial technology ecosystem leader empowering everyone to make their best financial decisions, today announced the appointment of Jon Kaplan as the company's first Chief Revenue Officer ("CRO"). Kaplan brings a wealth of experience and a proven track record of driving growth and innovation at iconic technology companies, including Pinterest (NYSE:PINS) and Google (NASDAQ:GOOG). In this role, Kaplan will lead MoneyLion's go-to-market strategy, with a focus on expanding the market share of MoneyLion's leading digital financial ecosystem. He will also leverage MoneyLion's data assets to deliver new revenue opportunities and drive success for MoneyLion'